# Week of April 29 – May 3, 2024

## OUHSC DEPARTMENT OF MEDICINE CONFERENCE SCHEDULE

**NOTE: All CME conferences will be designated by an \* by the name of the conference.**

|  |  |
| --- | --- |
| **Monday, April 29, 2024** |  |

 7:00 – 8:00 AM Internal Medicine Journal Club/CAT: AAT 6200

 12:15 – 1:15 PM Pulmonary and Critical Care Conference: Section Meeting VA/OU. AAT 8200

 2:00 – 3:00 PM Geriatric Medicine Fellowship Didactics: “Management of Diabetes and Other Thyroid/Parathyroid Disorders in Older Adults,” Panayiotis Tsitouras, MD, Professor Emeritus, Geriatrician, OUSHC. Zoom Meeting <https://zoom.us/j/95938242010?pwd=QU5RQnlBQkZlNXc3TmZhSTNqaHgxUT09>

 3:00 – 4:00 PM Hospice & Palliative Medicine Fellowship Didactics: “Board Review,” Cook (HPM) & Balogun (GMF). Zoom Meeting <https://zoom.us/j/95938242010?pwd=QU5RQnlBQkZlNXc3TmZhSTNqaHgxUT09>

|  |  |
| --- | --- |
| **Tuesday, April 30, 2024** |  |

 7:15 – 8:00 AM Cardiology Cath Conference: Board Review/Didactic Session. AAT 5200 or Zoom Meeting

 12:15 – 1:15 PM **\***Medicine Grand Rounds: “The Changing World of Type 1 Diabetes Mellitus,” David Sparling, MD, PhD, Associate Professor, Department of Pediatrics, CHF Paul and Ann Milburn Chair in Pediatric Diabetes and Endocrinology, Associate Chief, Section of Pediatric Diabetes and Endocrinology. Available by Zoom Meeting ID: 915 6165 6346 Passcode: 90357946 <https://zoom.us/j/91561656346?pwd=bmoxQVU0TTZCSjlSbTdXYUY3MFV0QT09> or join us by phone, 1-602-753-0140 (1.00 *AMA PRA Category 1 Credit™)*

Professional Practice Gap: The treatment of type 1 diabetes mellitus, despite having improved insulins and other treatment modalities, has not had a focus on root cause and possible prevention. With the expanding understanding of the autoimmune nature of diabetes, proper risk modeling resulting treatment strategies is now available. While novel treatments are being developed, insulin delivery modalities continue to evolve, allowing for more focused and real-time treatment goals for patients beyond the hemoglobin A1c. This talk will bring in to focus the evolving picture of type 1 diabetes diagnosis, prevention, and treatment.

 Learning Objectives: Upon completion of this session, participants will improve their competence and performance by being able to: Recognize risk factors to properly counsel high risk individuals and family members as to the risk of development of type 1 diabetes mellitus. Assess new treatment offerings and research into autoimmune causes of type 1 diabetes. Interpret the basics of new goals of treatment, including time in range.

|  |  |
| --- | --- |
|  **Wednesday, May 1, 2024** |  |

 7:00 – 8:00 AM Vascular Conference: AAT 9200

 8:00 – 9:00 AM Geriatric Journal Club: Zoom Meeting

 <https://zoom.us/j/98058292229?pwd=ejRsYzdlNGIrNkZjTytiMVUyd2NzUT09>

 8:15 – 9:00 AM ID Case Conference: AAT Conf Rm C

 12:15 – 1:00 PM Medicine House Staff Conference: “Resident Talk,” Aditia Bhamare, MD, Medicine Resident and Julie Nguyen, MD, Medicine Resident. AAT Conf Rm A&B

 12:15 – 1:15 PM Pulmonary and Critical Care Conference: “Management of Pain, Agitation and Delirium I the ICU – review of ABCDEF bundle,” Brent Brown, MD, Professor, Department of Medicine/Pulmonary. AAT 8200

 1:30 – 2:30 PM Renal Grand Rounds: Case Consultation: AAT 5328

 1:30 – 2:30 PM Rheumatology Clinical Conference: “Non-Operative Procedures/Injections,” Eldhose Abrahams, MD, Assistant Professor, Department of Anesthesiology, Interim Medical Director, Pain Medicine, Fellowship Program Director, Pain Management. Zoom Meeting

**Department of Medicine Conference Schedule April 29 – May 3, 2024**

|  |  |
| --- | --- |
| **Wednesday, May 1, 2024 Continued** |  |

 3:00 – 3:30 PM GI Pathophysiology Conference: “Hepatic Encephalopathy and Hepatorenal Syndrome 1486-1498 AASLD Guidelines Chapter 94,” Ralph Guild, MD, Professor, Department of Medicine/Digestive Diseases. SEC 3rd FL Conf Rm

 3:30 – 4:00 PM Digestive Disease and Nutrition Conference: “The Role of Endoflip in Evaluation of Upper Digestive Symptoms,” Ijlal Ali, MD, Assistant Professor, Department of Medicine/Digestive Diseases. SEC 3rd FL Conf Rm

 4:00 – 5:00 PM GI Motility Conference: “Anorectal Manometry,” Ijlal Ali, MD, Assistant Professor, Department of Medicine/Digestive Diseases. SEC 3rd FL Conf Rm

|  |  |
| --- | --- |
|  **Thursday, May 2, 2024** |  |

 7:15 – 8:00 AM Cardiovascular Grand Rounds: TBA/Speaker. Zoom Meeting

 12:15 – 1:00 PM Medicine House Staff Conference: “Resident Talk,” Laila Hashim, MD, Medicine Resident and Hussan Gill, MD, Medicine Resident. AAT Conf Rm A&B

 12:15 – 1:15 PM Pulmonary and Critical Care Conference: “Subarachnoid Hemorrhage – Initial Management and ICU,” Uttam Verma, MD, Assistant Professor, Department of Neurology. AAT 8200

|  |  |
| --- | --- |
| **Friday, May 3, 2024** |  |

 7:15 – 8:00 AM Echocardiography Conference: AAT 5200

 8:00 – 9:00 AM Hematology/Oncology Grand Rounds Conference: TBA/Mohamed Kharfan-Dabaja, MD, Professor of Medicine, Vice Chair of Hematology, Director of Blood Marrow and Transplant and Cellular Therapies, Mayo Clinic, Jacksonville, Florida. SCC 6039/Zoom Meeting

 12:15 – 1:00 PM Medicine House Staff Conference: IM Careers in Primary Care. AAT Conf Rm A&B

 12:15 – 1:15 PM Pulmonary and Critical Care Conference: Instructive Case Conference. AAT 8200

 1:30 – 2:30 PM Combined Thoracic-Oncology Clinical Care Conference: VAMC 5F-121

For accommodations on the basis of disability, call 405-271-6655 x1.

FUTURE EVENTS

May 27 Memorial Day 2024

To place name on mailing list or provide input for future schedules, contact Ms. Brenda Wilkerson, Department of Medicine. Schedules are typically e-mailed on Thursday of the week prior to the week of listed activities. If you wish to receive this via e-mail, you may use the Internet to request it. Address: Brenda-Wilkerson@ouhsc.edu

**Accreditation Statement:** The University Of Oklahoma College Of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Mitigation Statement:** The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity’s speaker and planner disclosures and has mitigated all relevant financial relationships with ineligible companies, if applicable.

**Acknowledgement of Commercial and In-Kind Support:** Commercial support is financial, or in-kind, contributions given by an ineligible company, which is used to pay all or part of the costs of a CME activity.  An ineligible company is any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity received no commercial or in-kind support.

**University of Oklahoma Equal Opportunity/Non-Discrimination Statement:** The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices, or procedures. This includes, but is not limited to: admissions, employment, financial aid, housing, services in educational programs or activities, or health care services that the university operates or provides.

To file a grievance related to the non-discrimination policy, report sexual misconduct, and/or file a formal complaint of sexual misconduct, please utilize the reporting form at [link.ou.edu/reportingform](file:///%5C%5Cdch-comd1%5Cdo%5Cocpd%5C22D%20RSS%202021-2022%5C22D%20To%20Do%5Clink.ou.edu%5Creportingform).

Inquiries regarding non-discrimination policies may be directed to the Office(s) of Institutional Equity as may be applicable – Norman campus: (405) 325-3546/3549, Health Sciences Center: (405) 271-2110, or OU-Tulsa Title IX Office: (918) 660-3107. Additionally, individuals may visit [www.ou.edu/eoo](http://www.ou.edu/eoo).

**Accommodations Statement:** For accommodations, please contact the Dept. of Medicine at 405-271-6651 ext. 1.

**Policy on Planner and Presenter Disclosure:** It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters identify all financial relationships with ineligible companies relating to the topics of this educational activity, and also discloses discussions of off-label or investigational drugs/devices and/or therapies during their presentation(s).

**Disclaimer Statement:** Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

**Disclosure & Mitigation Report**

The University of Oklahoma College of Medicine and the Irwin H. Brown Office of Continuing Professional Development must ensure balance, independence, objectivity and scientific rigor in all its accredited CE activities.  We have implemented a process where everyone who is in a position to control the content of an educational activity has identified to us all financial relationships with ineligible companies. In addition, should it be determined that a relevant financial relationship exists, this must be mitigated prior to the activity. This policy is designed to provide the target audience with an opportunity to review any affiliations between the CE planners and presenters and ineligible companies for the purpose of determining the potential presence of bias or influence over educational content. The following is a summary of this activity’s disclosure and mitigation information.

|  |  |  |
| --- | --- | --- |
| **Role**  | **First Name** | **Last Name**  | **Ineligible Company** | **Nature of the Financial Relationship** |
| Planning Committee/ Moderator | Adam S. | Asch, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee/ Moderator | Usman | Baber, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee/ Moderator | Mary Zoe | Baker, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee | Christopher | Beard, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Course Director/ Moderator | Michael S.  | Bronze, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee/ Moderator | Shouvik | Chakrabarty, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee/ Moderator | Benjamin D. | Cowley, Jr, MD | Otsuka | Consulting Fee |
| Sparrow Pharmaceuticals | Consulting Fee |
| **Planner:** Dr. Cowley has recused himself from planning content in the conflicted area. The CPD office has ensured that there are other planners without financial relationships who will control the content of the conflicted area. **Moderator:** Dr. Cowley will limit his role to the introduction of presenters, fielding questions, and moderating the flow of discussion between participants and presenters. **Presenter:** The conflict was mitigated by Dr. Crowley agreeing that the presentation will not include discussion of any products or services from any of the ineligible companies with which financial relationships exist. This presentation will be evaluated by participants for fair balance. |
| Planning Committee/ Moderator | Douglas A. | Drevets, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee | Courtney W. | Houchen, MD | COARE Biotechnology | Grants/Research  |
| **Planner:** Dr. Houchen has recused himself from planning content in the conflicted area. The CPD office has ensured that there are other planners without financial relationships who will control the content of the conflicted area. |
| Planning Committee  | Mary Beth | Humphrey, MD, PhD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee | Lee A. | Jennings, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Course Contact | Brenda E. | Wilkerson | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee  | Houssein | Youness, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Speaker | David | Sparling, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |